| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
1.25(B) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,161 |
| 52
Week Range: |
$9.29 - $32.855 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
272,263 |
272,263 |
366,330 |
484,412 |
| Total Sell Value |
$7,146,582 |
$7,146,582 |
$8,313,175 |
$9,294,074 |
| Total People Sold |
7 |
7 |
12 |
16 |
| Total Sell Transactions |
19 |
19 |
30 |
36 |
| End Date |
2025-09-13 |
2025-06-12 |
2024-12-12 |
2023-12-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dale Michael D |
Chief Executive Officer |
• – – |
2025-12-09 |
4 |
S |
$31.21 |
$1,918,137 |
D/D |
(61,463) |
88,537 |
|
2% |
|
| Kemp Jens |
Chief Marketing Officer |
• – – |
2025-12-09 |
4 |
S |
$31.21 |
$254,532 |
D/D |
(8,156) |
46,030 |
|
2% |
|
| Johnson John H |
Director |
– • – |
2025-12-09 |
4 |
S |
$29.98 |
$650,190 |
D/D |
(21,686) |
0 |
|
2% |
|
| Johnson John H |
Director |
– • – |
2025-12-09 |
4 |
OE |
$6.30 |
$53,834 |
D/D |
8,545 |
21,686 |
|
- |
|
| Began Marc A |
EVP & General Counsel |
• – – |
2025-12-09 |
4 |
S |
$31.21 |
$289,548 |
D/D |
(9,278) |
31,507 |
|
2% |
|
| Hartley Lindsey Marie |
CFO |
• – – |
2025-12-08 |
4 |
S |
$31.56 |
$454,005 |
D/D |
(14,387) |
31,376 |
|
3% |
|
| Hartley Lindsey Marie |
CFO |
• – – |
2025-12-08 |
4 |
OE |
$8.20 |
$345,400 |
D/D |
25,000 |
45,763 |
|
- |
|
| Johnson John H |
Director |
– • – |
2025-12-08 |
4 |
S |
$31.22 |
$740,203 |
D/D |
(23,693) |
13,141 |
|
3% |
|
| Johnson John H |
Director |
– • – |
2025-12-08 |
4 |
OE |
$6.30 |
$74,913 |
D/D |
11,891 |
25,032 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-11-11 |
4 |
AS |
$24.02 |
$86,249 |
D/D |
(3,591) |
100 |
|
36% |
|
| Burke Willaim P |
Director |
– • – |
2025-11-11 |
4 |
OE |
$8.14 |
$29,231 |
D/D |
3,591 |
3,691 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-11-10 |
4 |
AS |
$24.01 |
$461,640 |
D/D |
(19,227) |
100 |
|
39% |
|
| Burke Willaim P |
Director |
– • – |
2025-11-10 |
4 |
OE |
$8.14 |
$156,508 |
D/D |
19,227 |
19,327 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-11-06 |
4 |
AS |
$24.01 |
$128,371 |
D/D |
(5,347) |
100 |
|
39% |
|
| Burke Willaim P |
Director |
– • – |
2025-11-06 |
4 |
OE |
$8.14 |
$43,525 |
D/D |
5,347 |
5,447 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-11-05 |
4 |
AS |
$24.05 |
$274,893 |
D/D |
(11,431) |
100 |
|
43% |
|
| Burke Willaim P |
Director |
– • – |
2025-11-05 |
4 |
OE |
$8.14 |
$93,048 |
D/D |
11,431 |
11,531 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-10-30 |
4 |
AS |
$23.00 |
$419,704 |
D/D |
(18,248) |
100 |
|
47% |
|
| Burke Willaim P |
Director |
– • – |
2025-10-30 |
4 |
OE |
$7.04 |
$128,466 |
D/D |
18,248 |
18,348 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-10-29 |
4 |
AS |
$19.15 |
$827,013 |
D/D |
(40,235) |
100 |
|
50% |
|
| Burke Willaim P |
Director |
– • – |
2025-10-29 |
4 |
OE |
$6.30 |
$289,911 |
D/D |
40,235 |
19,899 |
|
- |
|
| Burke Willaim P |
Director |
– • – |
2025-10-22 |
4 |
AS |
$18.02 |
$26,252 |
D/D |
(1,457) |
100 |
|
85% |
|
| Burke Willaim P |
Director |
– • – |
2025-10-06 |
4 |
AS |
$18.00 |
$13,249 |
D/D |
(736) |
1,557 |
|
94% |
|
| Burke Willaim P |
Director |
– • – |
2025-10-03 |
4 |
AS |
$18.21 |
$265,283 |
D/D |
(14,571) |
2,293 |
|
86% |
|
| Burke Willaim P |
Director |
– • – |
2025-10-03 |
4 |
AS |
$18.21 |
$138,367 |
I/I |
(7,600) |
0 |
|
86% |
|
515 Records found
|
|
Page 1 of 21 |
|
|
0.60 (1.96%) 
